Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 7.15B |
| Revenue (ttm) | 89.12M |
| Net Income (ttm) | -109.59M |
| Shares Out | 103.87M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | 111.11 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $69.29 |
| Previous Close | $68.32 |
| Change ($) | 0.97 |
| Change (%) | 1.42% |
| Day's Open | 67.83 |
| Day's Range | 66.83 - 69.54 |
| Day's Volume | 537,921 |
| 52-Week Range | 32.86 - 93.66 |
This biotech underdog offers more than meets the eye.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided ...
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is the first tu...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim results on RNAi investigational medicine ARO-HIF2 in patients with renal cell carcinoma
A paused clinical trial with an important asset wasn't what investors wanted to hear today.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company's investigational RNA interference (R...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Takeda presented positive clinical trial data on rare orphan disease RNAi drug ARO-AAT at EASL The International Liver Congress
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD Society International Research Congress
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data at EASL showing ARO-HSD reduces HSD17B13 mRNA and protein in the liver leading to reductions in ALT
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pa...
PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at multiple conferences in June 2021
Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pha...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earns a $10 million option exercise fee from Janssen, part of Johnson & Johnson.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced financial results for its fiscal second quarter ended March 31, 2021.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated wi...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to ut...
In Q4 2020, we discussed why Arrowhead stock, a biopharmaceutical company that develops RNA interference therapies, looks attractive despite a stellar 16x move since early 2018. The stock has had a vola...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 566.67% over the past year to ($0.20)...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports fiscal 2021 first quarter earnings and holds a conference call
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NA...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021
ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intellect...
Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the past year...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings
These biotechs are fueling up for massive market launches.
Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference the...
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clin... [Read more...]
| Industry Biotechnology | IPO Date Jun 16, 1993 |
| CEO Christopher Anzalone | Employees 232 |
| Stock Exchange NASDAQ | Ticker Symbol ARWR |
Analyst Forecasts
According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 89.31, which is an increase of 28.89% from the latest price.